About Us

Charles Bidgood

Charles Bidgood


  • PhD Candidate (Cancer Metabolism), APCRC-Q
  • Centre for Genomics and Personalised Health, QUT
  • School of Biomedical Sciences, Faculty of Health, QUT

Contact Details

Linkedin profile


Bachelor of Biomedical Science (Honours), Queensland University of Technology, Australia, 2018

Bachelor of Biomedical Science (Human Physiology), Queensland University of Technology, Australia, 2017


Charles’ has been working with the APCRC-Q since 2018 where he joined as an honour’s student under the supervision of Jennifer Gunter, Martin Sadowski, Rohan Davis, and Colleen Nelson. His project involved investigating the use of naturally derived compounds to target prostate cancer metabolism. Here he developed a diverse skillset which included the implementation of high-content fluorescent microscopy and the generation of advanced image segmentation pipelines. In 2019, he began a PhD which was funded through the Australian Government Research Training Program (RTP) and is currently in his final year of research. His project involves investigating the complex metabolic landscape associated with advanced prostate cancer and the development of therapeutic resistance.

Awards and grants


    Heat Winner, QUT Biomedical Sciences 3 Minute Thesis Competition


    Best Speaker Award, TRI Student Seminar Series


    Australian Government Research Training Program (RTP) Scholarship


    Vacation Research Experience Scheme (VRES) Scholarship


    QUT Executive Dean's Commendation Award

Research interests

Prostate cancer, metabolism, fluorescent microscopy, bioinformatics

Current research projects

Valine Catabolism Reprogramming Promotes Therapeutic Resistance in Advanced Prostate Cancer

Top publications

Kumar, R., Bidgood, C. L., Levrier, C., Gunter, J. H., Nelson, C. C., Sadowski, M. C., &        Davis, R. A. (2020). Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell Imaging. Journal of Natural Products, 83(8), 2357–2366. https://doi.org/10.1021/acs.jnatprod.0c00121

Young, R. S. E., Bowman, A. P., Williams, E. D., Tousignant, K. D., Bidgood, C. L., Narreddula, V. R., Gupta, R., Marshall, D. L., Poad, B. L. J., Nelson, C. C., Ellis, S. R., Heeren, R. M. A., Sadowski, M. C., & Blanksby, S. J. (2021). Apocryphal FADS2 activity promotes fatty acid diversification in cancer. Cell Reports, 34(6), 108738. https://doi.org/10.1016/j.celrep.2021.108738

Philp, L. K., Rockstroh, A., Sadowski, M. C., Taherian Fard, A., Lehman, M., Tevz, G., Libério, M. S., Bidgood, C. L., Gunter, J. H., McPherson, S., Bartonicek, N., Wade, J. D., Otvos Jr, L., & Nelson, C. C. (2021). Leptin antagonism inhibits prostate cancer xenograft growth and progression. Endocrine-Related Cancer. https://doi.org/10.1530/erc-20-0405

More can be viewed on Pubmed.

More publications are available on PubMed


Professional memberships and associations


    Australian Society of Medical Research (ASMR)